


# Toll-Like Receptors (TLR) 7 and 8 Immune Pathway

## About TLR 7/8


A healthy immune response to pathogens plays a key role in protection from infection.

Toll-like receptors (TLR) 7 and 8 help detect the presence of certain pathogens in the body and help initiate and amplify both innate (nonspecific) and adaptive (specialized or specific) immune responses.<sup>1,2</sup>

These receptors in immune cells normally recognize single-stranded RNA (ssRNA) from pathogens (such as certain viruses) and activate various immune cells, resulting in an immune response.<sup>1,2</sup>




## TLR 7/8 and Inflammatory Diseases



An **uncontrolled or misdirected immune response** by the body can contribute to the damage of otherwise healthy cells, resulting in immune-mediated diseases.



**Overactivation of TLR7/8** contributes to inflammation that occurs in immune-mediated diseases.<sup>1,3</sup>



TLR7/8 can become overstimulated when the receptors recognize and are **activated by ssRNA released by damaged tissue**.<sup>1,3</sup>


Certain immune-mediated diseases, such as systemic lupus erythematosus, are associated with **defects in the body's ability to eliminate cell debris from tissue damage**, which can activate TLR7/8 and further contribute to the disease.<sup>4</sup>

TLR7 gain-of-function genetic variations may also be a driver for systemic lupus erythematosus.<sup>5</sup>

## Research Implications

Researchers are investigating potential ways to prevent the activation of the TLR7/8 pathway by blocking the receptors with small molecule inhibitors.<sup>6,7</sup>

This inhibition may help in the treatment of a range of immune-mediated diseases, such as lupus and other rheumatic diseases.<sup>7</sup>



At Bristol Myers Squibb, our investigation of immune pathways and receptors like TLR7/8 helps to deepen our understanding of disease and causal human biology and further our efforts to deliver meaningful solutions to patients with immune-mediated diseases.

### REFERENCES:

- Hayashi T, Gray CS, Chan M, et al. Prevention of Autoimmune Disease by Induction of Tolerance to Toll-like Receptor 7. *Proc Natl Acad Sci U S A*. 2009;106(8):2764-2769. doi: 10.1073/pnas.0813037106.
- Arpaia N, Barton GM. Toll-like Receptors: Key Players in Antiviral Immunity. *Curr Opin Virol*. 2011;1(6):447-454. doi:10.1016/j.coviro.2011.10.006
- Filatreau S, Manfroi B, Dörner T. Toll-like receptor signalling in B cells during systemic lupus erythematosus. *Nat Rev Rheumatol*. 2021;17(2):98-108. doi:10.1038/s41584-020-00544-4.
- Shao WH, Cohen PL. Disturbances of apoptotic cell clearance in systemic lupus erythematosus. *Arthritis Res Ther*. 2011;13(1):202. doi:10.1186/ar3206.
- Brown GT, Caiñete PF, Wang H, et al. TLR7 gain-of-function genetic variation causes human lupus. *Nature*. 2022;(605):349-356. doi: 10.1038/s41586-022-04642-z.
- Mussari CP, Dodd DS, Sreekantha RK, et al. Discovery of Potent and Orally Bioavailable Small Molecule Antagonists of Toll-like Receptors 7/8/9 (TLR7/8/9). *ACS Med Chem Lett*. 2020;11(9):1751-1758. doi:10.1021/acsmchemlett.0c00264.
- Sreekantha RK, Mussari CP, Dodd DS, et al. Identification of 2-Pyridinylindole-Based Dual Antagonists of Toll-like Receptors 7 and 8 (TLR7/8). *ACS Med Chem Lett*. 2022;13(5): 812-818. doi:10.1021/acsmchemlett.2c00049.